Mitesh J. Borad, MD

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Mitesh J. Borad, MD, discusses the unique mechanism of action of next-generation FGFR inhibitors like KIN-3248 and their potential effect on patient outcomes in cholangiocarcinoma and urothelial cancer.

Mitesh Borad, MD, discusses the next steps for investigating RLY-4008 in cholangiocarcinoma harboring FGFR2 fusion or rearrangement.

Sponsored Content

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.